Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2026

The following table represents a summary of warrants for the nine months ended September 30, 2026 and the year ended December 31, 2025:


	Nine Months Ended September 30, 2026				Year Ended December 31, 2025
	Number		Weighted Average Exercise Price		Number		Weighted Average Exercise Price
Beginning balance	5,653,981		$	2.05	8,744,698		$	1.40

Granted	—		—		8,666,667		1.15



Exercised	—		—		(8,509,926)		0.83





Expired	—		—		(3,247,458)		1.08
Ending balance	5,653,981		$	2.05	5,653,981		$	2.05

Warrants exercisable	5,653,981				5,653,981
Intrinsic value of warrants	$	—			$	—
Weighted Average Remaining Contractual Life (Years)	2.37				3.12

Schedule of Options

The following represents a summary of options granted under the terms of the Amended Plan and additional options granted outside of the Amended Plan, for the nine months ended September 30, 2026 and the year ended December 31, 2025:


	Number	Weighted Average Exercise Price		Weighted-Average Remaining Contractual Term (in Years)	Weighted Average Fair Value
Outstanding December 31, 2025	13,352,500	$	1.81	4.67	$	2.64
Granted	773,630	0.73		0	0.52
Exercised	(150,000)	0.35		0	0.13
Forfeited	(290,000)	1.49		0	1.42
Outstanding September 30, 2026	13,686,130	$	1.77	4.09	$	2.60

As of September 30, 2026
Vested and exercisable	9,858,313	$	1.89	3.70	$	2.17

Schedule of Stock Options, Valuation Assumptions

773,630 options were granted during the three months ended September 30, 2026. The following assumptions were used for the periods as follows:


	Nine Months Ended September 30, 2026	Year Ended December 31, 2025
Expected term	7 years	7 years
Expected volatility	71.74% – 172.22%	123.05% – 124.33%
Expected dividend yield	—	—
Risk-free interest rate	3.90% – 4.35%	3.90% - 4.14%